Dugel P, Jaffe G, Sallstig P, Warburton J, Weichselberger A, Wieland M et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 2017;124(9):1296-1304. September 2017.


Holz F, Dugel P, Weissgerber G, Hamilton R, Silva R, Bandello F et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2016;123(5):1080-1089.


Dugel P, Koh A, Ogura Y, Jaffe G, Schmidt-Erfurth U, Brown D et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72-84.


Jørstad Ø, Steffensen L, Eriksen K, Bragadóttir R, Moe M. Thirteen years of intravitreal anti‐vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway. Acta Ophthalmologica. 2019;.


Jørstad Ø, Faber R, Moe M. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmologica. 2017;95(5):460-463.


Kristiansen I, Haugli Bråten R, Jørstad Ø, Moe M, Sæther E. Intravitreal therapy for retinal diseases in Norway 2011–2015. Acta Ophthalmologica. 2019;98(3):279-285.

No votes yet

Medical Information Request


Ask Speakers